Boston CEO
Date: Location: Cost:
May 9 - 10, 2018 Four Seasons Boston
200 Boylston Street
Boston, MA 02116
(617) 338-4400

Starting at $1950

 

Dress Code:
Business Attire

Register

BOSTON CEO - MAY 9, 2018

2018 Steering Committee:
Kees Been, President and CEOLysosomal Therapeutics; Arthur Hiller, CEO, Antyllus Therapeutics; Jonathan LewisChairman & CEO, Samus Therapeutics; Imran Nasrullah, Director, BD&L, Strategic Partnering, Boehringer Ingelheim; Laurence Reid, President & CEO, Warp Drive Bio

Co-hosts and confirmed speakers include:
Michael BaileyPresident & CEO, Aveo Oncology; Andreas Busch, Global Head of R&D and Chief Scientific Officer, Shire; Grace Colon, President & CEO, InCarda Therapeutics; Ron Cooper, President & CEO, Albiero Pharma; Robert CoughlinPresident & CEO, MassBio; Michel Dahan, SVP, CBO, Akebia Therapeutics; John Hermann, Chief Strategy Officer and EVP, Oncology, Elstar Therapeutics; Edward KayeCEO, Stoke Therapeutics; Melissa KlugCBO, Keryx Biopharmaceuticals; Arthur Krieg, Founder & CEO, Checkmate Pharmaceuticals; Alison LawtonPresident & COO, Kaleido Biosciences; David Lucchino, Co-Founder, President & CEO, Frequency Therapeutics; John MaraganoreCEO, Alnylam; Corey McCannFounder and Chief Executive Officer, Pear Therapeutics; Arndt Rolfs, CEO, Centogene; Mark RotheraCEO, Orchard Therapeutics; Issi Rozen, CBO, The Broad Institute of Harvard & MIT; Phillip
Sharp
Co-Founder, Biogen; Praveen Tipirneni, CEO, Morphic Rock Therapeutics; Patrick TricoliCEO, Nanobiotix;  Michel VounatsosCEO, Biogen; 
Sue Washer, President and CEO, AGTC; Christoph WestphalCo-Founder & Partner, Longwood Fund

Time Agenda
7:45-8:45 am

Registration and Networking Breakfast

8:45-9:00 am

Welcome and Opening Remarks
Stephen Cutler, CEO, ICON

9:00-9:30 am

Moderated Keynote
John Maraganore, CEO, Alnylam
Moderator: Christoph Westphal, Co-Founder & Partner, Longwood Fund

9:30-10:00 am

State of the Industry
Ron Cooper, President & CEO, Albireo Pharma; Robert CoughlinPresident & CEO, Mass Bio; James Xue, Founder, Chairman & CEO, CANbridge Life Sciences
Moderator: David Barrow, Head of Healthcare for the Americas & Managing Director,  L.E.K. Consulting

10:00-10:30 am

Biotech Deal-Making and Collaborative Partnerships
Girish Aakalu, VP, Global Scientific Affairs & Scientific Intelligence, Ipsen Bioscience; Eric Falcand, SVP, Head of Business Developement & Licensing, Servier Monde; Kia Motesharei, Head of BD Neurology & Immunology, EMD Serono; Laurence Reid, CEO, Warp Drive Bio; Sue WasherPresident & CEOAGTC
Moderator: Melissa KlugCBO, Keryx Biopharmaceuticals

10:30-11:00 am

Networking Break

11:00-11:30 am

Raising Talent Capital
Michael Bailey, President & CEO, Aveo Oncology; Halley Gilbert, SVP, Chief Legal Officer, Ironwood Pharmaceuticals; Mark Rothera, President & CEO, Orchard Therapeutics; Praveen Tipirneni, CEO, Morphic Rock Therapeutics
Moderator: Cissy Young, Managing Director, Russel Reynolds

11:30-12:00 pm

Evolving Regulatory Landscapes: Generating Evidence for Regulatory Approval
John Alam, Founder and CEO, EIP Pharma, Inc; Thomas LonngrenFormer Executive Director, EMA; Gilmore O'Neill, SVP MS Franchise, Biogen
Moderator: Stephen Cutler, CEO, ICON

12:00-12:30 pm

Building a Biotech: Strategies for Success & Learning from Setbacks
Grace Colon, President & CEO, InCarda Therapeutics; John Hermann, Chief Strategy Officer and EVP, Oncology, Elstar Therapeutics; Alison Lawton, President & COO, Kaleido Biosciences; David Lucchino, Co-Founder, President & CEO, Frequency Therapeutics
Moderator: Laurence Reid, President & CEO, Warp Drive Bio

12:30-1:30 pm

Networking Lunch

1:30-2:00 pm

Utilizing Real World Data to Improve & Enhance Clinical Trials
Steven Perrin, CEO & CSO, ALS Therapy Development Institute; Arndt Rolfs, CEO, Centogene

2:00-3:00 pm

Therapeutic Market Focus
Jim Burns, President & CEO, Casebia Therapeutics; Philippe Lopes-FernandesSVP, Global Head of Licensing, BD & Alliance Management, EMD Serono; Matthew Henn, Executive VP Head of Drug Discovery, Seres Therapeutics; Thomas de Vlaam, CEO, Amylon Therapeutics
Moderator: Ryan DaviesCEOCurza

3:00-3:30 pm

Networking Break

3:30-4:00 pm

Leveraging Synthetic Biology for Biopharma Innovation
John Baldoni, Sr. VP, In Silico Discovery Performance Unit, GSK; Ena Cratsenburg, Chief Business Officer, Ginkgo Bioworks; Matthew Truppo; Executive Director, Merck 
Moderator: John Nicols, CEO, Codexis

4:00-4:30 pm

Fireside Chat: Emerging Technologies with the Potential to Disrupt the Current Biopharma Business Model
Corey McCann,
Founder & CEO, Pear Therapeutics
Moderator: Arthur Hiller, CEO, Antyllus Therapeutics

4:30-5:00 pm

Boston Biotech Lifetime Achievement Award
Honoring Biogen's 40th Anniversary 
Recipients: Professor Phillip Sharp, Co-Founder, Biogen; Michel Vounatsos, Chief Executive Officer, Biogen

5:00-6:00 pm

Cocktails and Hors d'oeuvres

BOSTON CEO - MAY 10, 2018

2018 Steering Committee:
Kees Been, President and CEOLysosomal Therapeutics; Arthur Hiller, CEO, Antyllus Therapeutics; Jonathan LewisChairman & CEO, Samus Therapeutics; Imran Nasrullah, Director, BD&L, Strategic Partnering, Boehringer Ingelheim; Laurence Reid, President & CEO, Warp Drive Bio

Co-hosts and confirmed speakers include:
Michael BaileyPresident & CEO, Aveo Oncology; Andreas Busch, Global Head of R&D and Chief Scientific Officer, Shire; Grace Colon, President & CEO, InCarda Therapeutics; Ron Cooper, President & CEO, Albiero Pharma; Robert CoughlinPresident & CEO, MassBio; Michel Dahan, SVP, CBO, Akebia Therapeutics; John Hermann, Chief Strategy Officer and EVP, Oncology, Elstar Therapeutics; Edward KayeCEO, Stoke Therapeutics; Melissa KlugCBO, Keryx Biopharmaceuticals; Arthur Krieg, Founder & CEO, Checkmate Pharmaceuticals; Alison LawtonPresident & COO, Kaleido Biosciences; David Lucchino, Co-Founder, President & CEO, Frequency Therapeutics; John MaraganoreCEO, Alnylam; Corey McCannFounder and Chief Executive Officer, Pear Therapeutics; Arndt Rolfs, CEO, Centogene; Mark RotheraCEO, Orchard Therapeutics; Issi Rozen, CBO, The Broad Institute of Harvard & MIT; Phillip
Sharp
Co-Founder, Biogen; Praveen Tipirneni, CEO, Morphic Rock Therapeutics; Patrick TricoliCEO, Nanobiotix;  Michel VounatsosCEO, Biogen; 
Sue Washer, President and CEO, AGTC; Christoph WestphalCo-Founder & Partner, Longwood Fund

Time Agenda
7:45-8:45 am

Registration and Networking Breakfast

8:45-9:00 am

Welcome and Opening Remarks
Robert Coughlin, President & CEO, Mass Bio

9:00-9:30 am

Healthcare Market Outlook 2018
Elcin Ergun Barker
Executive Vice President, Head of New Businesses, Merck Group; Bob SilvermanPersonalized Health Care (PHC) Business Strategy & Partnering, Roche Diagnostics Division and Molecular Solution
Moderator: Jonathan LewisChairman & CEO, Samus Therapeutics

9:30-10:00 am

Advancements in Oncology & Implications for the Future
Robert Beardsley
, Founder & COO, Galera Therapeutics; Michel Detheux, CEO, iTeos Therapeutics; Arthur Krieg, Founder & CEO, Checkmate Pharmaceuticals; Christopher LeMasters, CBO, Mirati Therapeutics
Moderator: Deborah Dunsire, MD, former CEO, Xtuit Pharmaceuticals

10:00-10:30 am

The New Frontier in Acadmic, Biotech and Pharma Partnering
Gabriela Apiou, Director of Translational Research Training & Development, Massachusetts General Hospital; Issi Rozen, CBO, The Broad Institute of Harvard and MIT; Patrick TricoliCEONanobiotix; James Zanewicz, Chief Business Officer, Tulane University;
Moderator: Chandra Ramanathan Ph.D., M.B.A, Head, East Coast Innovation Center, Bayer

10:30-11:00 am

Networking Break

11:00-12:00 pm

Drug Development and Partnerships in Global Markets
Michael Bailey
, President & CEO, Aveo Oncology; Michel Dahan, SVP, CBO, Akebia Therapeutics; Klaus D. Mendla, Global Head, Business Development and Licensing, CNS Boehringer Ingelheim; Paul-Peter TakSenior Vice President Immunology Network, GSK; Jin-San Yoo, President & CEO, PharmAbcine
Moderator: Steve Abrams, Partner, Hogan Lovells

12:00-12:30 pm

Market Access, Pricing & Reimbursement 
Scott ApplebaumPresidentContext Therapeutics; Mark RotheraCEO, Orchard Therapeutics
Moderator: Eileen CoveneySenior Partner, Biopharmaceuticals & Life Sciences, L.E.K. Consulting

12:30-1:30 pm

Networking Lunch

1:30-2:00 pm

Fireside Chat/Moderated Keynote
Moderator: Ian TzengManaging Director and Partner, L.E.K. Consulting

2:00-2:30 pm

Spotlight 
Andreas Busch, Global Head of R&D and Chief Scientific Officer, Shire

2:30-3:00 pm

CEO Roundtable
Edward KayeCEOStoke Therapeutics 
Moderator: Arthur KriegCEO, Checkmate Pharmaceuticals

3:00-3:15 pm

Closing Remarks

3:15-4:15 pm

Cocktails and Hors d'oeuvres

Executive Sponsors: (see all sponsors)

<